Pharmaron to acquire Wuxi Biortus Biosciences for 1.35 bn yuan

Pharmaron Beijing announced its intention to acquire an 82.54% equity interest in Wuxi Biortus Biosciences Co., Ltd. for a total consideration of 1,345,822,400 yuan. This strategic move aims to reinforce Pharmaron's "end-to-end, integrated, international, multi-modality" core strategy by enhancing its technology platforms, particularly in structural biology and complex drug target protein preparation. The acquisition will be funded by bank M&A loans (not less than 50%) and a portion of Pharmaron's own capital, integrating Biortus and its subsidiaries into Pharmaron's consolidated financial statements.

This transaction involves several related parties, including Beijing Kangjun Ningyuan Equity Investment Partnership, Ningbo Kangjun Zhongyuan Equity Investment Partnership, Ningbo Yufeng Venture Capital Partnership, and Beijing Junlian Huikang Equity Investment Partnership. These entities are controlled by key individuals at Pharmaron, including its actual controller and executive director and chief operating officer, making this a connected transaction. The deal was approved by Pharmaron's board of directors, with related directors abstaining, and is not subject to shareholder approval.